Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
Rhea-AI Summary
Citius Oncology (Nasdaq: CTOR) reported fiscal Q3 2026 results highlighted by initial LYMPHIR® commercialization. Revenue reached $1.5 million for the quarter and $7.1 million for the nine months ended June 30, 2026, versus no revenue a year earlier, generating gross profit of $1.0 million and $5.5 million, respectively.
Institutional demand for LYMPHIR continued to build, with vial orders from prescribing centers up 31% sequentially (926 vs. 708) and 44 institutions having ordered since launch. The company reported near-universal payer coverage and expanded its commercial and medical affairs field force to 29 professionals. Cash and equivalents totaled $16.6 million, supported by $9.7 million in warrant exercises and funding of $10.0 million from the first tranche of a $25.0 million term loan. CTOR recorded a Q3 net loss of $8.9 million and a nine‑month net loss of $41.1 million, driven largely by commercial build‑out and a one‑time $19.7 million CMO contract cancellation charge.
Positive
- Q3 2026 revenue $1.5M; nine‑month revenue $7.1M versus zero in 2025
- Institutional LYMPHIR demand up 31% QoQ to 926 vials; 44 institutions ordered
- Near‑universal LYMPHIR payer coverage with no reported reimbursement denials
- Cash and equivalents at June 30, 2026 of $16.6 million
- $9.7 million net proceeds from warrant exercises plus $10.0 million term loan funding
- R&D expenses reduced to $2.3 million for nine months from $5.3 million prior year
Negative
- Net loss of $8.9 million in Q3 and $41.1 million for nine months
- Nine‑month G&A of $30.7 million, including $19.7 million one‑time CMO contract cancellation
- Net cash used in operating activities of $13.9 million for nine months ended June 30, 2026
- Total liabilities increased to $71.7 million from $56.1 million at September 30, 2025
- License payments used $7.0 million of cash in investing activities
News Explained
As of
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 15 | Q2 earnings report | Negative | -24.8% | Commercial traction was offset by a $19.7 million cancellation charge and $26.6 million quarterly net loss. |
| May 15 | Q2 earnings report | Negative | -24.8% | Revenue growth accompanied a $21.2 million net loss and additional financing requirements. |
| Dec 23 | FY25 earnings report | Negative | -23.0% | Post-launch commercialization coincided with a $24.8 million net loss and financing activity. |
| Dec 23 | FY25 earnings report | Negative | -23.0% | Launch and financings accompanied a $39.7 million net loss and expanded distribution. |
| Aug 12 | Q3 earnings report | Positive | -1.5% | Raised $12.5 million in gross financings while preparing the LYMPHIR U.S. launch. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The tag-matched record showed negative reactions across five earnings events, with four aligned negative reactions and one divergence.
Key Terms
objective response rate medical
progression-free survival medical
complete response medical
partial response medical
senior secured term loan facility financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Strong institutional demand drives growth in total vials ordered and number of institutions ordering
LYMPHIR ordered by 44 institutions since launch
"Institutional demand (LYMPHIR vials ordered by prescribing centers from wholesalers) is accelerating. Institutional vial orders grew
"We expect continued institutional demand to drive new wholesaler orders. The Company recognizes revenue when wholesaler orders are fulfilled. Consequently, net revenue for any period reflects actual wholesaler orders fulfilled. In July, we began to see growth in institutional demand translate into increased wholesale orders and associated revenue. The positive trajectory of formulary approvals, institutional adoption, and unit demand gives us confidence in a robust remainder of the fiscal year," added Mazur.
"We generated initial momentum with a lean internal team, maintaining healthy product margins and securing broad market access. In August, our full 29-person-strong commercial and medical affairs organizations expanded to nationwide coverage. The teams are now positioned to accelerate commercial execution and support broader adoption by leveraging the comprehensive, scalable infrastructure already established for LYMPHIR, including patient hub services, marketing and reimbursement support. Citius Oncology is now well positioned to broaden engagement with treatment centers, targeting formulary inclusion at 100 priority institutions by year-end and first-in-class support for health care providers. At the same time, we continue to advance LYMPHIR's longer-term value proposition through investigator-initiated studies exploring its potential in combination regimens beyond CTCL," added Mazur.
"Overall, the launch is moving in the right direction: more institutions are ordering LYMPHIR, vial demand is increasing, and our commercial footprint is expanding. We believe the underlying increasing demand trends provide a strong basis for the remainder of fiscal 2026," concluded Mazur.
Fiscal Third Quarter 2026 Business Highlights and Subsequent Developments
- Secured prescriptions and orders from 44 institutions for LYMPHIR® (denileukin diftitox-cxdl), including academic oncology centers, leading National Comprehensive Cancer Network (NCCN) institutions, and community infusion centers;
- Increased the number of new ordering institutions by
80% in the quarter ended June 30, 2026, compared to the quarter ended March 31, 2026; - Grew the number of vials ordered by institutions from wholesalers by
31% in the quarter ended June 30, 2026, compared to the quarter ended March 31, 2026, with 383 institutional vials ordered in July 2026, the largest vial order month to date; - Secured near-universal payer coverage, with no reimbursement denials or prior authorization barriers reported to date;
- Expanded the commercial organization by 21 additional field-based professionals and added eight medical science liaisons, executed by the Company's exclusive commercialization partner, EVERSANA;
- Engaged
U.S . and international CTCL key opinion leaders at the Sixth World Congress of Cutaneous Lymphomas inMontreal through scientific exchange and educational initiatives; - Advanced two investigator-initiated Phase 1 studies of LYMPHIR in combination settings:
- Phase 1 data for LYMPHIR with pembrolizumab in recurrent or refractory gynecologic cancers presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrating:
- 20.5 months of median progression-free survival among
48% of efficacy-evaluable patients achieving clinical benefit (10 of 21), - Responses observed in patients previously treated with immune checkpoint inhibitors, including a
24% objective response rate (ORR) overall, and33% ORR in patients with relapsed or refractory endometrial cancer; and,
- 20.5 months of median progression-free survival among
- Phase 1 data for LYMPHIR administered prior to CAR-T therapy in high-risk relapsed or refractory diffuse large B-cell lymphoma (DLBCL) presented at 2026 ASTCT® & CIBMTR® Tandem Meetings, demonstrating:
86% ORR, including57% complete response (CR) and29% partial response (PR),- LYMPHIR was well-tolerated with no dose-limiting toxicities observed; and,
- Phase 1 data for LYMPHIR with pembrolizumab in recurrent or refractory gynecologic cancers presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrating:
- Appointed Jonathan Peri, Ph.D., J.D., as an independent director on August 10, 2026, bringing three decades of leadership experience across law, financial services and corporate governance.
Fiscal Third Quarter 2026 Financial Highlights and Subsequent Developments
- Cash and cash equivalents of
$16.6 million - Received approximately
$9.7 million $10.0 million $25.0 million - Revenues of
$1.5 million $7.1 million - Gross profit of
$1.0 million $5.5 million - Research and development (R&D) expenses of
$0.2 million $0.9 million $2.3 million $5.3 million - General and administrative (G&A) expenses of
$4.2 million $1.9 million $30.7 million $19.7 million - Net loss of
$8.9 million $(0.08) $5.4 million $(0.08) $41.1 million $(0.42) $19.8 million $(0.28)
About LYMPHIR™ (denileukin diftitox-cxdl)
LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin (DT) fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis, resulting in cell death. Denileukin diftitox-cxdl has demonstrated the ability to deplete immunosuppressive regulatory T lymphocytes (Tregs) and antitumor activity through a direct cytocidal action on IL-2R-expressing tumors. LYMPHIR was approved by the FDA and subsequently launched in the
About Citius Oncology, Inc.
Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In December 2025, Citius Oncology launched LYMPHIR, approved by the FDA for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Management estimates the initial CTCL market for LYMPHIR currently exceeds
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. Citius Pharma owns approximately
Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: our need for substantial additional funds and our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; our ability to regain compliance with Nasdaq's continued listing standards; the estimated markets for LYMPHIR and our product candidates and the acceptance thereof by any market; physician and patient acceptance of LYMPHIR in a competitive treatment landscape; our ability to obtain, perform under, and maintain third party agreements and relationships, including obtaining a new bulk drug substance supplier; our reliance on third-party logistics providers, distributors, and specialty pharmacies to support commercial operations; our ability to educate providers and payers, secure adequate reimbursement, and maintain uninterrupted product supply; our ability to secure and maintain strategic partnerships and expand international access to LYMPHIR; risks relating to the results of research and development activities; our ability to procure cGMP commercial-scale supply; risks related to our growth strategy; patent and intellectual property matters; government regulation; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings, which are available on the SEC's website at www.sec.gov, including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2025, filed with the SEC on December 23, 2025. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein, except as required by law.
Contacts
Investor Contact:
Ilanit Allen
ir@citiuspharma.com
908-967-6677 x113
Media Contact: STiR-communications
Greg Salsburg
greg@stir-communications.com
– Financial Tables Follow –
CITIUS ONCOLOGY, INC. | ||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||
(Unaudited) | ||||||||
June 30, | September 30, | |||||||
Current Assets: | ||||||||
Cash and cash equivalents | $ | 16,563,705 | $ | 3,924,908 | ||||
Accounts receivable, net of allowances | 686,235 | — | ||||||
Inventory | 22,625,945 | 22,286,693 | ||||||
Prepaid expenses | 2,831,280 | 1,331,280 | ||||||
Total Current Assets | 42,707,165 | 27,542,881 | ||||||
Other Assets: | ||||||||
In-process research and development, net of accumulated amortization | 69,385,938 | 73,400,000 | ||||||
Total Assets | $ | 112,093,103 | $ | 100,942,881 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current Liabilities: | ||||||||
Accounts payable | $ | 7,315,516 | $ | 13,234,684 | ||||
License payable | 15,650,000 | 22,650,000 | ||||||
Accrued expenses | 25,836,120 | 4,093,124 | ||||||
Due to related party | 9,985,558 | 9,513,771 | ||||||
Total Current Liabilities | 58,787,194 | 49,491,579 | ||||||
Notes payable, net of deferred financing costs | 6,410,161 | — | ||||||
Deferred tax liability | 2,710,643 | 2,784,960 | ||||||
Note payable to related party | 3,800,111 | 3,800,111 | ||||||
Total Liabilities | 71,708,109 | 56,076,650 | ||||||
Stockholders' Equity: | ||||||||
Preferred stock - | — | — | ||||||
Common stock - | 10,576 | 8,351 | ||||||
Additional paid-in capital | 145,481,984 | 108,897,836 | ||||||
Accumulated deficit | (105,107,566) | (64,039,956) | ||||||
Total Stockholders' Equity | 40,384,994 | 44,866,231 | ||||||
Total Liabilities and Stockholders' Equity | $ | 112,093,103 | $ | 100,942,881 | ||||
CITIUS ONCOLOGY, INC. | ||||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||
FOR THE THREE AND NINE MONTHS ENDED JUNE 30, 2026 AND 2025 (Unaudited) | ||||||||||||||||
Three Months Ended | Nine Months Ended | |||||||||||||||
June 30, | June 30, | June 30, | June 30, | |||||||||||||
2026 | 2025 | 2026 | 2025 | |||||||||||||
Revenues | $ | 1,493,788 | $ | — | $ | 7,105,197 | $ | — | ||||||||
Cost of revenues | (491,843) | — | (1,609,929) | — | ||||||||||||
Gross Profit | 1,001,945 | — | 5,495,268 | — | ||||||||||||
Operating Expenses | ||||||||||||||||
Research and development | 218,496 | 938,277 | 2,316,202 | 5,342,198 | ||||||||||||
Amortization of in-process research and development | 1,720,312 | — | 4,014,062 | — | ||||||||||||
General and administrative | 4,219,163 | 1,881,447 | 30,704,141 | 7,446,753 | ||||||||||||
Stock-based compensation – general and administrative | 3,560,791 | 2,125,237 | 11,043,551 | 6,022,287 | ||||||||||||
Total Operating Expenses | 9,718,762 | 4,944,961 | 48,077,956 | 18,811,238 | ||||||||||||
Operating Loss | (8,716,817) | (4,944,961) | (42,582,688) | (18,811,238) | ||||||||||||
Other Income (Expense) | ||||||||||||||||
Interest income | 96,848 | — | 168,857 | — | ||||||||||||
Gain on sale of | — | — | 1,762,000 | — | ||||||||||||
Amortization of deferred financing costs | (179,492) | — | (179,492) | — | ||||||||||||
Interest expense | (231,732) | (160,755) | (310,604) | (160,755) | ||||||||||||
Total Other Income (Expense), Net | (314,376) | (160,755) | 1,440,761 | (160,755) | ||||||||||||
Loss before Income Taxes | (9,031,193) | (5,105,716) | (41,141,927) | (18,971,993) | ||||||||||||
Income tax expense (benefit) | (107,347) | 264,240 | (74,317) | 792,720 | ||||||||||||
Net Loss | $ | (8,923,846) | $ | (5,369,956) | $ | (41,067,610) | $ | (19,764,713) | ||||||||
Net Loss Per Share - Basic and Diluted | $ | (0.08) | $ | (0.08) | $ | (0.42) | $ | (0.28) | ||||||||
Weighted Average Common Shares Outstanding | ||||||||||||||||
Basic and diluted (includes pre-funded warrants from the | 107,890,452 | 71,552,402 | 98,413,989 | 71,552,402 | ||||||||||||
CITIUS ONCOLOGY, INC. | ||||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||
FOR THE NINE MONTHS ENDED JUNE 30, 2026 AND 2025 | ||||||||
(Unaudited) | ||||||||
2026 | 2025 | |||||||
Cash Flows From Operating Activities: | ||||||||
Net loss | $ | (41,067,610) | $ | (19,764,713) | ||||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Stock-based compensation expense | 11,043,551 | 6,022,287 | ||||||
Amortization of in-process research and development | 4,014,062 | - | ||||||
Amortization of deferred financing costs | 179,492 | - | ||||||
Deferred income tax expense | (74,317) | 792,720 | ||||||
Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net of allowances | (686,235) | - | ||||||
Inventory | (339,252) | (8,940,201) | ||||||
Prepaid expenses | (1,500,000) | 1,600,000 | ||||||
Accounts payable | (5,919,168) | 4,955,797 | ||||||
Accrued expenses | 19,980,496 | 8,458,554 | ||||||
Due to related party | 471,787 | 6,875,556 | ||||||
Net Cash (Used In) Provided By Operating Activities | (13,897,194) | - | ||||||
Cash Flows From Investing Activities | ||||||||
License payments | (7,000,000) | - | ||||||
Net Cash Used In Investing Activities | (7,000,000) | - | ||||||
Cash Flows From Financing Activities | ||||||||
Net proceeds from notes payable | 9,635,000 | - | ||||||
Net proceeds from exercise of warrants and pre-funded warrants | 9,730,818 | - | ||||||
Deferred Financing Costs | (892,551) | |||||||
Net proceeds from issuance of common stock | 15,062,724 | - | ||||||
Net Cash Provided by Financing Activities | 33,535,991 | - | ||||||
Net Change in Cash and Cash Equivalents | 12,638,797 | - | ||||||
Cash and Cash Equivalents – Beginning of Period | 3,924,908 | 112 | ||||||
Cash and Cash Equivalents – End of Period | $ | 16,563,705 | $ | 112 | ||||
Supplemental Disclosures of Cash Flow Information and Non-cash Transactions: | ||||||||
Interest Paid | $ | 212,794 | $ | - | ||||
Warrants issued for loan agreement included in deferred financing costs | $ | 749,280 | $ | - | ||||
Deferred financing costs included in accrued expenses | $ | 1,762,500 | $ | - | ||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-oncology-inc-reports-fiscal-third-quarter-2026-financial-results-and-provides-business-update-302852117.html
SOURCE Citius Oncology, Inc.